Progyny, Inc. (NASDAQ:PGNY) Receives $25.00 Average PT from Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have been given an average rating of “Hold” by the thirteen research firms that are currently covering the company, Marketbeat reports. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $25.00.

PGNY has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of Progyny in a research report on Tuesday, October 1st. JPMorgan Chase & Co. restated a “neutral” rating and set a $17.00 price objective (down from $22.00) on shares of Progyny in a research report on Monday, December 2nd. Jefferies Financial Group dropped their target price on shares of Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Truist Financial reissued a “hold” rating and set a $19.00 target price (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Finally, Canaccord Genuity Group decreased their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PGNY. State Street Corp raised its holdings in shares of Progyny by 4.5% during the 3rd quarter. State Street Corp now owns 3,113,654 shares of the company’s stock worth $52,185,000 after acquiring an additional 134,861 shares during the period. International Assets Investment Management LLC increased its position in Progyny by 1,576.0% during the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company’s stock worth $42,991,000 after purchasing an additional 2,412,068 shares during the last quarter. Pacer Advisors Inc. raised its stake in Progyny by 12,579.4% during the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company’s stock worth $41,777,000 after purchasing an additional 2,472,983 shares during the period. Invenomic Capital Management LP acquired a new position in Progyny in the 3rd quarter valued at about $29,509,000. Finally, Farallon Capital Management LLC grew its stake in shares of Progyny by 120.8% in the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock valued at $37,436,000 after buying an additional 715,900 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Performance

PGNY stock opened at $14.86 on Tuesday. The firm’s fifty day moving average is $15.57 and its 200 day moving average is $21.46. The firm has a market cap of $1.27 billion, a PE ratio of 25.62, a P/E/G ratio of 1.66 and a beta of 1.35. Progyny has a one year low of $13.39 and a one year high of $42.08.

Progyny (NASDAQ:PGNY) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The business had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. Progyny’s revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the business earned $0.16 earnings per share. Research analysts predict that Progyny will post 0.59 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.